-
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
13 Dec 2024 19:55 GMT
… previously announced merger with Pieris Pharmaceuticals, Inc. (Pieris). The … BioCapital, Petrichor, CAM Capital, Ligand Pharmaceuticals, Integrated Finance Group (an … existing partnership agreements with Pfizer and Boston Pharmaceuticals, in addition to …
-
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
10 Dec 2024 14:20 GMT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will … future GAAP financial results.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling … biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, …
-
Ligand to Present at Stifel 2024 Healthcare Conference
14 Nov 2024 13:16 GMT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today … their Stifel representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling … biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, …
-
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
07 Nov 2024 12:14 GMT
… 47;/www.ligand.com.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical … companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences … earnings per diluted share.
LIGAND PHARMACEUTICALS INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS …
-
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
01 Nov 2024 12:16 GMT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today … conclusion of the event.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling … biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, …
-
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
23 Oct 2024 20:17 GMT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today … call are available here.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling … biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, …
-
OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?
22 Oct 2024 13:29 GMT
… Takeda, Organon, Regeneron, and Pfizer.
Atopic dermatitis (AD) is a … first co-stimulatory receptor−ligand pair expressed on APCs … Professional APC and OX40-Ligand
AD inflammation is orchestrated … in Autoimmune Diseases. Front Pharmacol. 2018;9:642.
Harryvan …
-
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)
16 Oct 2024 12:00 GMT
… the gabapentinoid class, represented by Pfizer’s Lyrica® (pregabalin) approved … humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being … . Investor Contact Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862 …
-
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2024 Earnings Call Transcript
07 Aug 2024 12:45 GMT
… Session
Follow Ligand Pharmaceuticals Inc (NASDAQ:LGND) Follow Ligand Pharmaceuticals Inc (NASDAQ … with the existing product. Pfizer’s, PREVNAR clearly the … November.
Follow Ligand Pharmaceuticals Inc (NASDAQ:LGND) Follow Ligand Pharmaceuticals Inc (NASDAQ: …
-
MET Targeting Therapies Market Set for Significant Growth by 2034: Key Trends and Insights | DelveInsight
18 Dec 2024 18:00 GMT
… of various cells, with a ligand known as hepatocyte growth factor … , EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech … SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong …
About
© 1995-2024